Clinical trial

Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer

NCT03438318

Study summary

ClinicalTrials.gov

Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention CMP-001 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Atezolizumab Normalized identity: atezolizumab View linked drug · Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention Radiation Therapy Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-03-15

PhasePHASE1

Conditions

Non Small Cell Lung Cancerunresolved

Interventions

CMP-001DRUG

AtezolizumabDRUG · verified · RxNorm: atezolizumab

Radiation TherapyRADIATION

Sponsors & collaborators

Regeneron Pharmaceuticalslead sponsor

Novella Clinicalcollaborator

Mapped research locations

HoustonTexas, United States1 AuroraColorado, United States1 Iowa CityIowa, United States1 DuarteCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03438318 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.